Skip to main content

Table 3 Multivariate logistic regression analysis for independent risk factors associated with CACS ≥300

From: Coronary artery calcium score plays an important role for cardiovascular risk stratification in the statin benefit groups of asymptomatic individuals

  Moderate-intensity statin therapy group High-intensity statin therapy group
Odds ratio 95% CI p-value Odds ratio 95% CI p-value
Age 1.206 0.990–1.470 0.062 1.299 1.137–1.483 <0.001
Gender, male 6.726 0.149–302.635 0.326 44.252 1.959–999.784 0.017
Body mass index 0.834 0.491–1.415 0.501 1.095 0.735–1.632 0.655
Waist circumference 0.984 0.841–1.150 0.838 0.956 0.838–1.089 0.498
Systolic BP 1.015 0.901–1.144 0.801 1.066 0.999–1.138 0.053
Diastolic BP 1.027 0.884–1.194 0.723 0.988 0.889–1.097 0.816
Heart rate 0.969 0.901–1.097 0.906 0.958 0.895–1.025 0.215
Total cholesterol 1.010 0.850–1.105 0.635 1.056 0.978–1.139 0.164
Triglyceride 1.049 0.987–1.035 0.385 0.990 0.973–1.007 0.232
HDL-C 1.021 0.900–1.221 0.542 0.901 0.800–1.015 0.087
LDL-C 0.977 0.893–1.168 0.757 0.944 0.872–1.022 0.155
Fasting blood glucose 0.753 0.837–1.141 0.773 1.046 1.007–1.087 0.021
HbA1c 1.734 0.087–6.551 0.797 1.034 0.321–3.325 0.956
Fasting insulin 0.131 0.261–11.521 0.569 1.525 0.931–2.499 0.094
HOMA-IR 1.279 0.000–377.759 0.617 0.235 0.041–1.346 0.104
C reactive protein 0.879 0.809–2.024 0.292 0.249 0.008–8.009 0.432
Ten-year ASCVDS 0.948 0.386–1.999 0.758 0.967 0.831–1.127 0.669
  1. *Statin benefit group was defined as individuals who should be considered moderate- and high-intensity statin therapy
  2. CAC coronary artery calcium, CI confidence intervals, BP blood pressure, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, HOMA-IR homeostasis model assessment insulin resistance, ASCVD atherosclerotic cardiovascular disease